Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Endometrial Neoplasms 9Stomach Neoplasms 8Melanoma 8Carcinoma, Renal Cell 8Squamous Cell Carcinoma of Head and Neck 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Carcinoma, Hepatocellular 6Breast Neoplasms 6Pancreatic Neoplasms 5Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Head and Neck Neoplasms 4Esophageal Neoplasms 4Carcinoma, Merkel Cell 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Sarcoma 2Recurrence 2Microsatellite Instability 2Lymphoma 2Kidney Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma 2Vulvar Neoplasms 1

Interventions

atezolizumab 1HhAntag691 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Platinum-Resistant Fallopian Tube Carcinoma × atezolizumab × Gynecologic × Clear all
NCT05538091 2025-11-26

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

University of Pittsburgh

Phase 2 Recruiting
48 enrolled
Gynecologic

Platinum-Resistant Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡